Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001233680 | SCV001406285 | uncertain significance | Cohen syndrome | 2022-06-20 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 1264 of the VPS13B protein (p.Pro1264Ser). This variant is present in population databases (rs527263178, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 960201). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002563236 | SCV003653234 | uncertain significance | Inborn genetic diseases | 2022-10-03 | criteria provided, single submitter | clinical testing | The c.3790C>T (p.P1264S) alteration is located in exon 25 (coding exon 24) of the VPS13B gene. This alteration results from a C to T substitution at nucleotide position 3790, causing the proline (P) at amino acid position 1264 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001233680 | SCV002082526 | uncertain significance | Cohen syndrome | 2021-04-28 | no assertion criteria provided | clinical testing |